Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State Universi...
September 07 2017 - 08:00AM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
that it has entered into a preclinical research collaboration with
The Ohio State University Comprehensive Cancer Center – Arthur G.
James Cancer Hospital and Richard J. Solove Research Institute
(OSUCCC – James) focused on TIL, marrow-infiltrating lymphocyte
(MIL) and peripheral blood-associated lymphocyte technologies.
The collaboration will initially focus on hematologic
malignancies in areas of poor prognostic cancers with high unmet
medical need, which include acute myeloid leukemia (AML) and
chronic lymphocytic leukemia (CLL). The collaboration will be
co-led by Iovance researchers and by Dr. John Byrd, D. Warren Brown
Chair of Leukemia Research, Distinguished University Professor of
Medicine, Medicinal Chemistry and Veterinary Biosciences at the
OSUCCC – James.
“We are very pleased to collaborate with the OSUCCC – James and
Dr. Byrd, who brings an impressive track record and expertise in
the preclinical and clinical development of ground-breaking
hematological therapies,” said Maria Fardis, Ph.D., MBA, President
and Chief Executive Officer of Iovance Biotherapeutics. “Our
initial internal work in developing TIL in hematologic malignancies
will be presented at the upcoming ESMO 2017 Congress and that work,
along with our collaboration with the OSUCCC – James, shows our
continued efforts in exploring the utilization of TIL therapy in
hematological oncology indications, in addition to our ongoing
clinical work in solid tumor indications.”
“TIL directed therapy is an exciting novel application to both
AML and CLL and our research team at the OSUCCC – James is excited
to be part of this collaborative research to explore this new
treatment approach,” said Dr. Byrd.
About Iovance Biotherapeutics, Inc. Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology company
focused on the development of cancer immunotherapy products for the
treatment of various cancers. The Company's lead product candidate
is an adoptive cell therapy using tumor-infiltrating lymphocyte
(TIL) technology being investigated for the treatment of patients
with metastatic melanoma, recurrent and/or metastatic squamous cell
carcinoma of the head and neck and recurrent and metastatic or
persistent cervical cancer. For more information, please
visit http://www.iovance.com.
Forward-Looking Statements Certain matters
discussed in this press release are “forward-looking statements.”
The Company may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. The
forward-looking statements include risks and uncertainties,
relating to the Company’s ability to advance its global development
programs and the efficacy of its immune-oncology TIL therapies, the
successful implementation of its research collaboration with The
Ohio State University, the timing and cost of that collaboration,
its ability to develop TIL for hematologic oncology indications and
solid tumor indications, and the results of the Company’s own
research and development program in the utilization of TIL in
hematologic indications. A further list and description of the
Company’s risks, uncertainties and other factors can be found in
the Company’s most recent Annual Report on Form 10-K and the
Company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or www.iovance.com. The forward-looking statements are
made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstance.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
evan.smith@fticonsulting.com
kotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2023 to Mar 2024